MoneyBall Medicine

Niven Narain and How AI and Machine Learning Are Changing Drug Discovery

Episode Summary

Harry interviews Niven Narain, the co-founder, president and CEO of Berg, a Boston-based biopharma company driving the next generation of drugs and diagnostics by combining patient-driven biology and AI to unravel actionable disease insight. Narain has overseen development of Berg’s clinical stage assets and pipeline and forged strategic partnerships with industry academic and US and UK governments. He says Berg's philosophy is to combine a systems biology architecture with patients' demographic data and clinical outcome data, and then apply Bayesian artificial intelligence algorithms to drive better understanding of diseases.

Episode Notes

Harry interviews Niven Narain, the co-founder, president and CEO of Berg, a Boston-based biopharma company driving the next generation of drugs and diagnostics by combining patient-driven biology and AI to unravel actionable disease insight. Narain has overseen development of Berg’s clinical stage assets and pipeline and forged strategic partnerships with industry academic and US and UK governments. He says Berg's philosophy is to combine a systems biology architecture with patients' demographic data and clinical outcome data, and then apply Bayesian artificial intelligence algorithms to drive better understanding of diseases.

To learn more visit glorikian.com/podcast/

How to rate MoneyBall Medicine on iTunes with an iPhone, iPad, or iPod touch: